Table I. Immunoprecipitation of HIV-1 Ba-L–containing supernatant media from infected MDM cultures.
| Virus precipitation
|
Expression in MDM
|
||||
|---|---|---|---|---|---|
| Percentage of infectivity in supernatanta | Percentage of p24 precipitated | n b | Cell surfacec | Intracellulard | |
| Viral antigens | |||||
| HIV-1 Env (b12) | 0.3 ± 0.7 | 92.2 ± 8.1 | 5 | ND | ND |
| Control | 100 | 14.2 ± 2.7 | 5 | − | − |
| MHCII | |||||
| HLA-DR | 29.4 ± 8.4 | 79.6 ± 4.3 | 5 | +++ | ++ |
| Tetraspanin | |||||
| CD63 (1B5) | 5.6 ± 2.1 | 95.5 ± 3.4 | 4 | + | ++++ |
| CD63 (FC5.01) | 6.6 | 100 | 1 | ND | ++++ |
| CD81 | 84.5 ± 9.5 | 39.6 ± 16.5 | 3 | +++ | ++ |
| CD82 | 75.1 ± 18.8 | 51.2 ± 7.0 | 3 | + | + |
| CD53 | 58.7 ± 8.0 | 58.6 ± 16.3 | 3 | ++ | ND |
| CD151 | 85.0 ± 21.3 | 12.2 ± 5.5 | 3 | ++ | +/− |
| Lysosome associated | |||||
| LAMP-1 | 54.5 | 40.2 | 1 | − | +++ |
| LAMP-2 | 115.8 | 21.2 | 1 | − | ++ |
| GPI anchored | |||||
| CD14 | 87.8 ± 16.8 | 11.9 ± 7.3 | 3 | ++ | +/− |
| CD52 | 94.6 ± 11.6 | 18.4 ± 8.0 | 3 | ++ | +/− |
| CD55 | 88.3 ± 16.7 | 9.5 ± 5.2 | 3 | + | +/− |
| CD59 | 45.4 ± 17.6 | 67.0 ± 9.0 | 3 | +/+ | + |
| Adhesion | |||||
| CD11a | 110.3 ± 28.4 | 18.4 ± 5.1 | 3 | ++ | +/− |
| CD54 | 56.3 | 20.0 | 1 | +++ | ND |
| CD169 | 96.8 ± 17.5 | 17.5 ± 1.7 | 3 | ++ | +/− |
| Scavenger receptor | |||||
| CD163 | 103.2 ± 20.3 | 17.1 ± 4.4 | 3 | + | +/− |
ND, not determined.
a
To calculate the percentage of infectivity in the supernatant, the infectivity of samples treated with the control antibody against VSV-G was set at 100%.
b
Number of experiments.
c
Determined by FACS® analysis or by immunofluorescence.
d
Determined by immunofluorescence staining of semi-thin cryosections or of permeabilized cells.